Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.
Charles A. Leath III MD
Advertisement
Articles by Charles A. Leath III MD
Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.
Charles A. Leath, III, MD, gynecologic oncologist, The University of Alabama at Birmingham, discusses challenges with bevacizumab in the treatment of patients with cervical cancer.
Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.
Advertisement
Latest Updated Articles
Dr. Leath on Challenges With Bevacizumab in Cervical CancerPublished: March 5th 2019 | Updated:
Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical CancerPublished: November 7th 2019 | Updated:
Dr. Leath on Agents Under Investigation in Cervical CancerPublished: November 15th 2019 | Updated:
Dr. Leath Discusses Unmet Need in Cervical CancerPublished: January 20th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5